Healthcare
Live Price
Offline$221.38
+0.00% today
Window Change
+392.50%
Window
Jun 23, 2025 โ Jan 8, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 139 bars ยท Jun 23, 2025 โ Jan 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cidara Therapeutics, Inc. (CDTX) is a Healthcare stock with a market cap of $5.61B. The stock last traded around $221.38 and up 392.5% across the available one-year price window (Jun 23, 2025 โ Jan 8, 2026). Baseline metrics include revenue growth of -94.5%, EPS growth of -409.5%, a dividend yield of 0.0%. What stands out right now is revenue -94.5%, EPS -409.5%, free cash flow -670.2% with operating margin 0.0% and ROIC -46.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CDTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-94.5% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2025 was reported on Nov 6, 2025 with an EPS surprise of -6.7%.
The operating picture looks softer than before
Revenue is at -94.5% and EPS is at -409.5%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.3% over the next 5 trading days and finished higher after 3 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Nov 6, 2025 | -6.7% | +5.8% | +7.5% | +123.4% |
2025 Aug 7, 2025 | +11.8% | +0.4% | +2.9% | +2.3% |
2025 May 8, 2025 | +69.5% | +4.2% | +8.4% | +36.9% |
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CDTX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
CDTX Max Drawdown
-19.83%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CDTX and SPY.
Company Overview
Cidara Therapeutics, Inc.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.